Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, c1995-

Multiple Myeloma*/drug therapy ; Multiple Myeloma*/pathology ; Antineoplastic Agents*/adverse effects; Humans ; Proteasome Inhibitors/pharmacology ; Proteasome Inhibitors/therapeutic use ; Proteasome Endopeptidase Complex ; Bortezomib/therapeutic use

Multiple myeloma (MM) is an aggressive and incurable disease for most patients, characterized by periods of treatment, remission and relapse. The introduction of new classes of drugs, such as proteasome inhibitors (PIs), has improved survival outcomes in these patient populations. The proteasome is the core of the ubiquitin-proteasome system (UPS), a complex and conserved pathway involved in the control of multiple cellular processes, including cell cycle control, transcription, DNA damage repair, protein quality control and antigen presentation. To date, PIs represent the gold standard for the treatment of MM. Bortezomib was the first PI approved by the FDA, followed by next generation of PIs, namely carfilzomib and ixazomib. Natural agents play an important role in anti-tumor drug discovery, and many of them have recently been reported to inhibit the proteasome, thus representing a new potential source of anti-MM drugs. Based on the pivotal biological role of the proteasome and on PIs' significance in the management of MM, in this review we aim to briefly summarize recent evidence on natural compounds capable of inhibiting the proteasome, thus triggering anti-MM activity.

Redox Biol. 2021 May;41:101897. (PMID: 33640701)
Cancer Res. 2000 Nov 15;60(22):6465-71. (PMID: 11103814)
Cancers (Basel). 2022 Jun 16;14(12):. (PMID: 35740630)
Br J Haematol. 2016 Sep;174(5):711-20. (PMID: 27161872)
Curr Protein Pept Sci. 2018 Feb 13;19(4):358-367. (PMID: 28079010)
J Cell Commun Signal. 2011 Jun;5(2):101-10. (PMID: 21484190)
Nat Rev Clin Oncol. 2017 Jul;14(7):417-433. (PMID: 28117417)
Biomed Res Int. 2016;2016:6504593. (PMID: 26881223)
Nat Rev Mol Cell Biol. 2018 Nov;19(11):697-712. (PMID: 30065390)
Blood. 2012 Aug 2;120(5):947-59. (PMID: 22645181)
Cancer Metastasis Rev. 2017 Dec;36(4):561-584. (PMID: 29196868)
J Nat Prod. 2016 Mar 25;79(3):629-61. (PMID: 26852623)
Redox Biol. 2013 Jan 19;1:178-82. (PMID: 24024151)
Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):1305-1310. (PMID: 28115689)
J Cell Biochem Suppl. 1997;27:59-67. (PMID: 9591194)
J Nat Prod. 2020 Mar 27;83(3):770-803. (PMID: 32162523)
Cancers (Basel). 2021 Mar 11;13(6):. (PMID: 33799793)
Mol Cancer. 2013 Aug 10;12:91. (PMID: 23937906)
J Mol Biol. 2017 Nov 10;429(22):3500-3524. (PMID: 28583440)
In Vivo. 2012 Mar-Apr;26(2):197-202. (PMID: 22351658)
Leuk Res. 2020 Jan;88:106271. (PMID: 31778912)
Mol Plant Microbe Interact. 2004 Jan;17(1):90-7. (PMID: 14714872)
Molecules. 2021 Oct 31;26(21):. (PMID: 34771006)
Cancers (Basel). 2021 May 29;13(11):. (PMID: 34072312)
Eur J Med Chem. 2011 Oct;46(10):4769-807. (PMID: 21889825)
J Antibiot (Tokyo). 2001 Dec;54(12):997-1003. (PMID: 11858671)
Mol Cancer Ther. 2009 Aug;8(8):2286-95. (PMID: 19671755)
Expert Opin Ther Targets. 2017 Jan;21(1):91-101. (PMID: 27892767)
Cancers (Basel). 2021 Apr 28;13(9):. (PMID: 33924959)
J Food Sci. 2007 Apr;72(3):S207-11. (PMID: 17995816)
Mol Cancer Ther. 2005 Aug;4(8):1277-85. (PMID: 16093444)
Pharmacol Rev. 2019 Apr;71(2):170-197. (PMID: 30867233)
Planta Med. 2010 Aug;76(11):1064-74. (PMID: 20186654)
Leukemia. 2014 Jun;28(6):1326-33. (PMID: 24317448)
Blood. 2009 Jun 4;113(23):5927-37. (PMID: 19190249)
Eur J Pharmacol. 2019 Jun 15;853:184-192. (PMID: 30928629)
J Cell Biochem. 2008 Jan 1;103(1):234-44. (PMID: 17541980)
J Antibiot (Tokyo). 2017 May;70(5):542-550. (PMID: 28196975)
Curr Cancer Drug Targets. 2011 Mar;11(3):239-53. (PMID: 21247388)
Oncotarget. 2012 Oct;3(10):1246-58. (PMID: 23100393)
Nat Rev Dis Primers. 2017 Jul 20;3:17046. (PMID: 28726797)
Curr Med Chem. 2020;27(2):187-215. (PMID: 29956610)
Gene. 2003 Mar 13;306:1-12. (PMID: 12657462)
Oncogene. 2014 Dec 11;33(50):5655-65. (PMID: 24469030)
Noncoding RNA. 2020 Sep 09;6(3):. (PMID: 32916806)
Mol Cancer Res. 2007 Sep;5(9):943-55. (PMID: 17855663)
Int J Mol Sci. 2018 Jan 16;19(1):. (PMID: 29337925)
Blood. 2009 Apr 23;113(17):4027-37. (PMID: 19096011)
Acta Pharmacol Sin. 2018 Mar;39(3):492-498. (PMID: 29168472)
Mol Cancer. 2010 May 19;9:112. (PMID: 20482842)
Biol Chem. 1999 Oct;380(10):1201-9. (PMID: 10595583)
Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(1):12-36. (PMID: 19145068)
Blood. 2016 Jun 2;127(22):2693-700. (PMID: 27009059)
Biochem Pharmacol. 2013 Jun 1;85(11):1579-87. (PMID: 23499879)
J Exp Ther Oncol. 2014;10(4):275-83. (PMID: 25509983)
Cell Cycle. 2013 Dec 1;12(23):3650-62. (PMID: 24091729)
J Antibiot (Tokyo). 2001 Dec;54(12):1004-12. (PMID: 11858653)
Expert Opin Biol Ther. 2013 Jun;13 Suppl 1:S125-37. (PMID: 23692413)
Biosci Rep. 2022 Feb 25;42(2):. (PMID: 35088066)
J Biol Chem. 2016 Apr 15;291(16):8350-62. (PMID: 26907687)
Jpn J Clin Oncol. 2018 Sep 1;48(9):785-793. (PMID: 30102324)
Leukemia. 2002 Apr;16(4):433-43. (PMID: 11960320)
Cancer Sci. 2014 Dec;105(12):1609-15. (PMID: 25251038)
Biomed Pharmacother. 2016 Apr;79:112-9. (PMID: 27044819)
Lancet Oncol. 2016 Aug;17(8):e328-e346. (PMID: 27511158)
Int J Mol Sci. 2022 Oct 27;23(21):. (PMID: 36361848)
Pharmacol Rev. 2012 Oct;64(4):972-1003. (PMID: 22966038)
Eur J Med Chem. 2017 May 5;131:222-236. (PMID: 28329729)
Histol Histopathol. 2008 Apr;23(4):487-96. (PMID: 18228206)
Science. 2016 Aug 5;353(6299):594-8. (PMID: 27493187)
Nat Rev Drug Discov. 2005 Mar;4(3):206-20. (PMID: 15729362)
Cancer Cell. 2012 Sep 11;22(3):345-58. (PMID: 22975377)
ACS Med Chem Lett. 2012 Sep 11;3(10):789-92. (PMID: 24900381)
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:457-476. (PMID: 31479618)
Mol Cell. 2001 Jun;7(6):1143-52. (PMID: 11430818)
Molecules. 2016 Jul 16;21(7):. (PMID: 27438821)
Carcinogenesis. 1998 Apr;19(4):611-6. (PMID: 9600345)
Clin Cancer Res. 2013 Sep 1;19(17):4559-63. (PMID: 23775332)
Nat Rev Clin Oncol. 2017 Feb;14(2):100-113. (PMID: 27531699)
Drugs. 2016 Mar;76(3):405-11. (PMID: 26846321)
Cancer Lett. 2005 Dec 8;230(1):111-21. (PMID: 16253767)
Nature. 2008 Apr 10;452(7188):755-8. (PMID: 18401409)
Nat Rev Drug Discov. 2021 Mar;20(3):200-216. (PMID: 33510482)
Medicines (Basel). 2019 Mar 07;6(1):. (PMID: 30866563)
Nat Commun. 2021 Oct 26;12(1):6173. (PMID: 34702852)
Nat Commun. 2020 Jan 24;11(1):477. (PMID: 31980598)
Cancers (Basel). 2020 Jan 30;12(2):. (PMID: 32019064)

IG24449 Italian Association for Cancer Research; GR-2016-02361523 Italian Ministry of Health; PRIN 2017 - 201744BN5T Ministry of Education, Universities and Research

Keywords: multiple myeloma; natural compounds; proteasome; proteasome inhibitors

0 (Proteasome Inhibitors)
EC 3.4.25.1 (Proteasome Endopeptidase Complex)
0 (Antineoplastic Agents)
69G8BD63PP (Bortezomib)

Date Created: 20230211 Date Completed: 20230214 Latest Revision: 20230214

20231215

PMC9919276

10.3390/molecules28031438

36771100